CLINICAL TRIALS PROFILE FOR LUCINACTANT
✉ Email this page to a colleague
All Clinical Trials for Lucinactant
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00004500 ↗ | Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome | Terminated | Windtree Therapeutics | Phase 3 | 2000-03-01 | OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants. |
NCT00215540 ↗ | SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. | Terminated | Windtree Therapeutics | Phase 2 | 2005-02-01 | SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS). |
NCT00215553 ↗ | KL₄Surfactant Treatment in Patients With ARDS | Terminated | Windtree Therapeutics | Phase 2 | 2001-05-01 | Lung wash with KL₄Surfactant of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with acute respiratory distress syndrome(ARDS). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lucinactant
Condition Name
Clinical Trial Locations for Lucinactant
Trials by Country
Clinical Trial Progress for Lucinactant
Clinical Trial Phase
Clinical Trial Sponsors for Lucinactant
Sponsor Name